{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:56:40Z","timestamp":1791176200903,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.antiviral.2015.01.003","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T23:19:27Z","timestamp":1421709567000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region"],"prefix":"10.1016","volume":"116","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Lathouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemie","family":"Buelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Witek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2202-9990","authenticated-orcid":false,"given":"Yves","family":"Wyckmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-3545","authenticated-orcid":false,"given":"Bart","family":"Fevery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ghys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.01.003_b0005","unstructured":"AASLD\/IDSA Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http:\/\/www.hcvguidelines.org\/full-report-view. Date accessed: 16th September 2014."},{"key":"10.1016\/j.antiviral.2015.01.003_b9005","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0010","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.01.003_b0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2013.06.029","article-title":"Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies","volume":"444","author":"Barnard","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0020","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.01.003_b0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1128\/AAC.01976-13","article-title":"Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir","volume":"58","author":"Berger","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.01.003_b0030","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1053\/j.gastro.2013.11.047","article-title":"Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C","volume":"146","author":"Buti","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2008.02.001","article-title":"Changing HCV genotypes distribution in Poland\u2014relation to source and time of infection","volume":"42","author":"Chlabicz","year":"2008","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2015.01.003_b0040","unstructured":"Clinicaltrials.gov. An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01571583?term=VX-950HPC3006&rank=1. Date accessed: 19th August 2014."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.01.003_b0045","first-page":"A47","article-title":"Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3\/4A inhibitors","volume":"18","author":"De Luca","year":"2013","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2015.01.003_b0055","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.25962","article-title":"Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial","volume":"56","author":"De Meyer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0060","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/infdis\/jiu340","article-title":"Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3\u20134A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study","volume":"210","author":"Dierynck","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2015.01.003_b0065","unstructured":"Dieterich, D., Bacon, B.R., Flamm, S.L., Kowdley, K.V., Milligan, S., Tsai, N., Younossi, Z., Lawitz, E. et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Presented at AASLD 2014 Abstract 46. Available at: http:\/\/www.natap.org\/2014\/AASLD\/AASLD_09.htm. EASL Recommendations on Treatment of Hepatitis C 2014. Available at: http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C.pdf. Date accessed: 16th September 2014."},{"key":"10.1016\/j.antiviral.2015.01.003_b0070","unstructured":"Fevery, B., Thys, K., Van Eygen, V., Verbinnen, T., Van Rossem, E., Picchio, G., De Meyer, S., Lenz, O., 2014. EASL International Liver Congress 2014. Poster 220. Available at: http:\/\/www.natap.org\/2014\/EASL\/EASL_62.htm."},{"key":"10.1016\/j.antiviral.2015.01.003_b0075","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0080","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00efve genotype 1 hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0085","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/hep.22773","article-title":"Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy","volume":"49","author":"Gaudieri","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0090","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/JCM.41.10.4855-4857.2003","article-title":"Evaluation of the TRUGENE HCV 5\u2032NC genotyping kit with the new Gene Librarian module 3.1.2 for genotyping of hepatitis C virus from clinical specimens","volume":"41","author":"Germer","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2015.01.003_b0095","first-page":"45","article-title":"HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C","volume":"18","author":"Grigorescu","year":"2009","journal-title":"J. Gastrointest. Liver Dis."},{"key":"10.1016\/j.antiviral.2015.01.003_b0100","article-title":"Characterization of hepatitis C virus inter-genotypic recombinant strains and associated virologic response to sofosbuvir\/ribavirin","author":"Hedskog","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0105","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0110","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.01.003_b0120","unstructured":"Jacobson, I.M, Dore, G.J., Foster, G.R., Fried, M., Manns, M., Marcellin, P., Poordad, F., Affonso de Araujo, E.S., Peeters, M., Lenz, O., Ouwerkerk-Mahadevan, S., De La Rosa, G., Kalmeijer, R., Sinha, R., Beumont-Mauviel, M., 2013. Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-na\u00efve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials. In: 64rd Annual Meeting of the American Association for the Study of Liver Diseases. Poster presentation. Available at: http:\/\/www.natap.org\/2014\/APASL\/APASL_19.htm. Date accessed: 16th September 2014."},{"key":"10.1016\/j.antiviral.2015.01.003_b0125","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","article-title":"Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients","volume":"48","author":"Kuntzen","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-62703-484-5_12","article-title":"Amplification and sequencing of the hepatitis C virus NS3\/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b","volume":"1030","author":"Koletzki","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2015.01.003_b0135","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.01.003_b0140","doi-asserted-by":"crossref","unstructured":"McCloskey, R.M., Liang, R.H., Joy, J.B., Krajden, M., Montaner, J.S.G., Harrigan, P.H., Poon, A.F.Y., 2014. Global origin and transmission of hepatitis C virus NS3 Q80K polymorphism. [Epub ahead of print].","DOI":"10.1093\/infdis\/jiu613"},{"key":"10.1016\/j.antiviral.2015.01.003_b0145","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2014.06.023","article-title":"Patients eligible for treatment with simeprevir in a French center","volume":"61","author":"Morel","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2015.01.003_b0155","doi-asserted-by":"crossref","unstructured":"Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M., Buelens A., Beumont-Mauviel M., Picchio G, De Meyer S., 2014. Virology analyses of simeprevir in Phase 2b and 3 studies. EASL International Liver Congress 2014. Poster 221. Available at: http:\/\/www.natap.org\/2014\/EASL\/EASL_63.htm. Date accessed: 16th September 2014.","DOI":"10.1016\/S0168-8278(14)60383-4"},{"key":"10.1016\/j.antiviral.2015.01.003_b0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2015.01.003_b0165","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.01.003_b0170","unstructured":"Moreno, C., H\u00e9zode, C., Marcellin, P., Bourgeois, S., Francque, S., Samuel, D., Zoulim, F., Grange, J.-D., Lenz, O., Ouwerkerk-Mahadevan, S., Peeters, M., Beumont-Mauviel, M., Jessner, W. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin in treatment-na\u00efve or treatment-experienced chronic HCV genotype 4-infected patients: final results of a Phase III trial. 2014 EASL International Liver Congress 2014. Poster P1319. Abstract available at: http:\/\/www.professionalabstracts.com\/ilc2014\/planner\/index.php?go=abstract&action=abstract_show&absno=3712&ILC2014=8d20f7okaone2akbib0ks0efauotgv13. Date accessed: 16th September 2014."},{"key":"10.1016\/j.antiviral.2015.01.003_b0175","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0180","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.01.003_b0185","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2893.2010.01342.x","article-title":"Evidence for separation of HCV subtype 1a into two distinct clades","volume":"18","author":"Pickett","year":"2011","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.antiviral.2015.01.003_b0190","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","author":"Pilot-Matias","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.01.003_b0195","unstructured":"Reddy, K.R., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C., Villamil, F., Andreone, P., George, J., Dammers, E., Fu, M., Kurland, D., Lenz, O., Ouwerkerk-Mahadevan, S., Verbinnen, T., Jessner, W. A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study. Asian Pacific Association for the Study of the Liver 2014. Oral Presentation. Available at: http:\/\/www.natap.org\/2014\/APASL\/APASL_20.htm. Date accessed: 16th September 2014."},{"key":"10.1016\/j.antiviral.2015.01.003_b0200","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1155\/2014\/604942","article-title":"Telaprevir activity is unaffected by the Q80K polymorphism in hepatitis C virus genotype 1a","volume":"28","author":"Shafran","year":"2014","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2015.01.003_b0210","unstructured":"Simeprevir Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002777\/WC500167867.pdf. Date accessed 16th September 2014."},{"key":"10.1016\/j.antiviral.2015.01.003_b0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1515\/CCLM.2007.043","article-title":"Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays","volume":"45","author":"Stelzl","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0220","unstructured":"Sulkowski, M.S., Vargas, H.S., Di Bisceglie, A.M., Kuo, A., Reddy, K.R., Lim, J.K., Morelli, M., Feld, J.J., Brown, R.S., Frazier, L.M., Fried, M.W., Nelson, D.R., Jacobson, I.M., 2014. Safety and efficacy of sofosbuvir (SOF) in combination with simeprevir (SIM)+Ribavirin (RBV) in patients with genotype 1: interim results of a prospective, observational study. Presented at AASLD 2014. Abstract 955. Available at: http:\/\/www.natap.org\/2014\/AASLD\/AASLD_10.htm."},{"key":"10.1016\/j.antiviral.2015.01.003_b0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0230","unstructured":"Verbinnen, T., Fevery, B., Vijgen, L., Picchio, G., De Meyer, S., Lenz, O., 2014. Phenotypic characterisation of genotype 1 hepatitis C NS3 protease variants from clinical studies with simeprevir. Presented at the International Workshop on Antiviral Drug Resistance, Berlin, Germany."},{"key":"10.1016\/j.antiviral.2015.01.003_b0235","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2015.01.003_b0240","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T21:24:13Z","timestamp":1589491453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":47,"alternative-id":["S0166354215000042"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}